DE2138317A1 - Neues substituiertes Carbamoyloxychinolin und Verfahren zu seiner Herstellung - Google Patents
Neues substituiertes Carbamoyloxychinolin und Verfahren zu seiner HerstellungInfo
- Publication number
- DE2138317A1 DE2138317A1 DE19712138317 DE2138317A DE2138317A1 DE 2138317 A1 DE2138317 A1 DE 2138317A1 DE 19712138317 DE19712138317 DE 19712138317 DE 2138317 A DE2138317 A DE 2138317A DE 2138317 A1 DE2138317 A1 DE 2138317A1
- Authority
- DE
- Germany
- Prior art keywords
- trichloro
- preparation
- carbamoyloxyquinoline
- quinoline
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 6
- NEOCJLWBSDEGCI-UHFFFAOYSA-N quinolin-2-yl carbamate Chemical class C1=CC=CC2=NC(OC(=O)N)=CC=C21 NEOCJLWBSDEGCI-UHFFFAOYSA-N 0.000 title description 3
- 241000233866 Fungi Species 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 239000005725 8-Hydroxyquinoline Substances 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 229960003540 oxyquinoline Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- QOAMKXAKNOVDBW-UHFFFAOYSA-N (5,6,7-trichloroquinolin-8-yl) N-methylcarbamate Chemical compound ClC1=C2C=CC=NC2=C(C(=C1Cl)Cl)OC(NC)=O QOAMKXAKNOVDBW-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- UCYJDCBBSWMOTP-UHFFFAOYSA-N 5,6,7-trichloroquinolin-8-ol Chemical compound C1=CN=C2C(O)=C(Cl)C(Cl)=C(Cl)C2=C1 UCYJDCBBSWMOTP-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 208000005373 Dyshidrotic Eczema Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010056430 Staphylococcal sepsis Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 229910001651 emery Inorganic materials 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000005005 intertrigo Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/32—Esters
- C07D215/34—Carbamates
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7028116A FR2097047B1 (Direct) | 1970-07-30 | 1970-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2138317A1 true DE2138317A1 (de) | 1972-02-03 |
Family
ID=9059489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712138317 Pending DE2138317A1 (de) | 1970-07-30 | 1971-07-30 | Neues substituiertes Carbamoyloxychinolin und Verfahren zu seiner Herstellung |
Country Status (7)
| Country | Link |
|---|---|
| BE (1) | BE770567A (Direct) |
| CH (1) | CH542846A (Direct) |
| DE (1) | DE2138317A1 (Direct) |
| FR (1) | FR2097047B1 (Direct) |
| GB (1) | GB1355198A (Direct) |
| IL (1) | IL37358A0 (Direct) |
| NL (1) | NL7110552A (Direct) |
-
1970
- 1970-07-30 FR FR7028116A patent/FR2097047B1/fr not_active Expired
-
1971
- 1971-07-21 CH CH1075571A patent/CH542846A/fr not_active IP Right Cessation
- 1971-07-21 IL IL37358A patent/IL37358A0/xx unknown
- 1971-07-27 BE BE770567A patent/BE770567A/xx unknown
- 1971-07-29 GB GB3577071A patent/GB1355198A/en not_active Expired
- 1971-07-30 DE DE19712138317 patent/DE2138317A1/de active Pending
- 1971-07-30 NL NL7110552A patent/NL7110552A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB1355198A (en) | 1974-06-05 |
| FR2097047A1 (Direct) | 1972-03-03 |
| IL37358A0 (en) | 1971-10-20 |
| FR2097047B1 (Direct) | 1974-08-30 |
| BE770567A (fr) | 1972-01-27 |
| NL7110552A (Direct) | 1972-02-01 |
| CH542846A (fr) | 1973-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3120460C2 (Direct) | ||
| DE2804097A1 (de) | 1-ethyl-6-fluor-1,4-dihydro-7-(1- piperazinyl)-4-oxochinolin-3-carbonsaeure, ihre hydrate und salze mit saeuren | |
| DE2421121A1 (de) | Neue chinoline und verfahren zu ihrer herstellung | |
| DE3205655C2 (Direct) | ||
| DE2102172C3 (de) | Neue Mittel zur Behandlung und Pflege der Haut | |
| DE2552869C2 (de) | Pharmazeutische Zusammensetzungen mit Piperidylindol-Derivaten | |
| DE2739661C3 (de) | Jodderivat von Benzalkoniumchlorid und dieses enthaltendes Arzneimittel | |
| DE69313640T2 (de) | Zink-tranexamat derivat | |
| DE2140719A1 (de) | Arzneimittel auf der Grundlage eines Pyrazolons | |
| DE1900974C3 (de) | 2,6-Diphenyl-3-methyl-23-dihydroimidazo [2,1 -b] thiazol, dessen Herstellung und dieses enthaltende pharmazeutische Zusammensetzungen | |
| DE1545699A1 (de) | Neue Aminopyrazole | |
| DE2515594C3 (de) | Verfahren zur Herstellung eines stabilen, topisch aktiven Geles | |
| DE2745598A1 (de) | Arylschwefelverbindungen, verfahren zu ihrer herstellung und sie enthaltendes pharmazeutisches mittel | |
| DE1917739A1 (de) | Neue Derivate der Thiocarbamidsaeure | |
| DE2407937A1 (de) | 5-nitro-2-thiazolylthio-substituierte heterocyclische verbindungen | |
| DE2138317A1 (de) | Neues substituiertes Carbamoyloxychinolin und Verfahren zu seiner Herstellung | |
| DE69915504T2 (de) | Produkte für körperhygiene basierend auf lapacho extrakte enthaltend quercetin, deren herstellung und verwendung | |
| DE1793272C3 (de) | 2-(4'-Chlorbenzyl)-phenole, deren Herstellung und Arzneimittel, die diese Verbindungen enthalten | |
| DE2166270A1 (de) | Aminoaethansulfonylderivate | |
| DE2934166A1 (de) | 1,3-benzoxazin-2,4-dion-derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| DE1695849A1 (de) | Verfahren zur Herstellung neuer Pyrimidinderivate | |
| DE1620054C (de) | Verfahren zur Herstellung von Chinolindenvaten sowie diese Ver bindungen enthaltende Arzneimittel Ausscheidung aus 1470047 | |
| DE951629C (de) | Verfahren zur Herstellung von substituierten 4-Oxyhydrindenen | |
| DE1445560A1 (de) | N-Dichlorbenzyl-4-alkyl-pyridiniumsalze | |
| DE2154608A1 (de) | Neues Diacetat, pharmazeutische Präparate und Herstellungsverfahren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHJ | Non-payment of the annual fee | ||
| OI | Miscellaneous see part 1 |